Table 5.
FMT for IBD (RCTs and case serieses)
| Author, year | Design | Disease activity |
Case /Ctrl |
FMT route and others | Outcomes, thrapy vs control | PMID |
|---|---|---|---|---|---|---|
| Ulcerative colitis | ||||||
| Borody, 2003 | Cases | active | 6/0 | Enema, pre-antibiotics | Clinical response: 100% at 4 m | 12811208 |
| Kunde, 2013 | Cases | active | 10/0 child | Enema | Clinical response: 78% at 1 w Clinical remission: 33% at 1 w | 23542823 |
| Moayyedi, 2015 | RCT | active | 36/34 | Enema, multiple | Improve remission rate (24% vs 5%) at 7 w | 25857665 |
| Rossen, 2015 | RCT | active | 23/25 | Nasoduodenal, multiple | NS (41% vs 25%, in per-protocol population) at 12 w | 25836986 |
| Damman, 2015 | Cases | active | 7/0 | Colonoscopy | Clinical remission: 14% from 1 m until 3 m | 26288277 |
| Suskind, 2015 | Cases | active | 4/0 child | Nasogastric | NS | 25647155 |
| Wei, 2015 | Cases | active | 11/0 | Colonoscopy or nasojejunal | Improve Mayo score and IBDQ score at 4 w | 26146498 |
| Wei, 2016 | Cases | active | 10/10 | FMT vs FMT +pectin (FMTP) | Mayo scores were significantly lower in the FMTP group than in the FMT at 4 w and 12 w | 27809778 |
| Vermeire, 2016 | Cases | active | 8/0 | Colonoscopy or nasojejunal | Endoscopic remission: 25% at 8 w | 26519463 |
| Goyal, 2016 | Cases | active | 7/0 | Colonoscopy or nasojejunal | Clinical response: 16% at 180 d | Abst (a) |
| Paramsothy, 2017 | RCT | active | 42/43 | Single colonoscopy and multiple enema, pooled FMT | Improve remission rate (27% vs 8%) at 8 w | 28214091 |
| Jacob, 2017 | Cases | active | 20/0 | Colonoscopy | Clinical response: 35% Clinical remission: 15% Mucosal healing 10% at 4 w | 28445246 |
| Uygun, 2017 | Cases | active | 30/0 | Colonoscopy | Clinical response: 70% Clinical&Endoscopic remission: 43% at 12 w | 28422836 |
| Ishikawa, 2017 | Cases | active | 17/19 | Colonoscopy, pre-AFM antibiotics + FMT vs AFM alone | Pre-AFM contributed to Bacteroidetes recovery associated with UC activity at 4 w | 27893543 |
| Nishida, 2017 | Cases | active | 41/0 | Colonoscopy | Clinical response: 27% at 8 w | 27730312 |
| Goyal, 2018 | Cases | active | 14/0 child | Single upper and lower endoscopy | Clinical response: 50% Clinical remission: 0% at 6 m | 29361092 |
| Costello, 2019 | RCT | active | 38/35 | Enema and colonoscopy, anaerobically prepared pooled FMT | Improve remission rate (32% vs 9%) at w8 42% of responder keep remission at 12 m | 30644982 |
| Pouchitis | ||||||
| Landy, 2015 | Cases | active | 8/0 | Nasogastric | Clinical response: 25% Clinical remission: 0% | 26264409 |
| El-Nachef, 2016 | Cases | active | 7/0 | Pouchoscopy | Improve symptoms (71%) | Abst (b) |
| Stallmach, 2016 | Cases | active | 5/0 | multiple | Clinical response: 100% Clinical remission: 4/5 | 27018122 |
| Herfarth, 2019 | RCT -> open | active | 6/0 | Single colonoscopy and daily oral | Clinical remission: 17% at 2 w | 31172007 |
| Selvig, 2019 | Cases | active | 19/0 | Single colonoscopy | NS on clinical activity Improve bowel movement frequency and abd pain, microbial diversity at 4 w | 31302808 |
| Crohn’s disease | ||||||
| Suskind, 2015 | Cases | active | 9/0 child | Nasogastric | Remission: 78% at 2 w | 25647155 |
| Cui, 2015 | Cases | active | child 30/0 | Gastroscope+mid-gut tube | Response (87%), remission (77%) | 25168749 |
| Wei, 2015 | Cases | active | 3/0 | Conoloscopy or nasogastric | NS (clinical activity) Improve IBDQ score at 4 w | 26146498 |
| Vanghn, 2016 | Cases | active | 19/0 | Colonoscopy | Clinical response (58%) Increase in colonic regulatory T cells at 12 w | 27542133 |
| Vermeire, 2016 | Cases | active | 6/0 | Colonoscopy or nasojejunal | NS | 26519463 |
| Goyal, 2016 | Cases | active | 4/0 child | Nasojejunal and colonoscopy | Response: 75% at 180 d | Abst (a) |
| He, 2017 | Cases | active | 25/0 | Colonoscopy + tube | Response: 68%, Remission: 52% reduce inflammatory mass | 28684845 |
| Goyal, 2018 | Cases | active | 7/0 child | Single upper and lower endoscopy | Response: 71%, remission: 29% at 6m | 29361092 |
| Li, 2019 | Cases | active | 165/0 | Mid-gut/nasal-jejunal transendoscopic enteral tubing | Analysis of timing for sencond FMT Second<4 m is better | 30357440 |
IBD: inflammatory bowel disease, FMT, fecal microbiota transplantation, RCT: randomized controlled trial, PMID: PubMed identifier, NS: no statistically significant difference in disease activity, IBDQ: inflammatory bowel disease questionnaire, AFM: amoxicillin, fosfomycin, metronidazole. Abst (a): JPGN 2016, 63, S212, Abst (b): Gastroenterology 2016, 150, S544.